NEW YORK, Oct. 13 /PRNewswire-USNewswire/ — The
U.S. Food and Drug Administration’s approval of Alkermes’ opioid
dependence medication (VIVITROL) for the prevention of relapse to
opioid dependence following opioid detoxification is positive news
for families of young adults and all those who are struggling to
overcome opioid addiction. Addiction, a disease of the human
brain, is a chronic illness while opioid dependence is frequently
characterized by relapse.
“Opioid dependence, whether from misuse of prescription pain
medications or illicit use of heroin, is one of the most imperative
health issues facing our nation, and as an organization, we have
devoted significant resources to help families find appropriate
treatment for a loved one with an addiction and support that person
in recovery,” said Steve Pasierb, President and Chief Executive
Officer of The Partnership at Drugfree.org. “This new
indication for Alkermes’ product as a non-addictive approach to
prevent relapse to opioid dependence in people age 18 and older
brings hope to the families we serve. Our view is that this
medication must be used in concert with appropriate addiction
treatment services and psychosocial support.”
Parents are at the center of the organization’s mission, and The
Partnership at Drugfree.org recently unveiled a new name and
expanded resources, providing them with answers and support at
whatever their stage of need, from prevention to recovery.
Among these new offerings are dedicated treatment
resources on drugfree.org, and specifically,
Time To Get Help,
a comprehensive tool that includes information on how to obtain a
proper assessment, identify and pay for appropriate treatment and
connect with other parents who have had their own family
experiences with substance abuse and addi
‘/>”/>
